Ilaprazole for the Treatment and Prevention of Peptic Ulcer Bleeding in Chinese Patients
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this phase study is to confirm the efficacy and safety by compare ilaprazole
and omeprazole in the treatment and prevention of peptic ulcer bleeding. Patients with
endoscopically diagnosed peptic ulcer bleeding were enrolled in a multi-center, stratified
randomized, non-inferiority test, double-blind, parallel and positive-controlled trial. They
were randomly assigned into two groups, ilaprazole and omeprazole, to be treated for up to 30
days. The primary endpoint was the hemostasis rate at the end of 72 hours. Secondary end
points include ulcer staging changes within 72 hours, effective rate of hemostasis,
hemostasis duration, average blood transfusion and rebleeding rate, etc.